Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 14/20 | 0.66 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.49 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.48 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4763434 | 0.89 | SYK (0.67) | SYKAURKALRRK2TBK1JAK2 | |
| SCHEMBL4775395 | 0.86 | SYK (0.60) | SYKAURKALRRK2CDK2TBK1 | |
| SCHEMBL4766530 | 0.85 | AURKA (0.55) | SYKAURKALRRK2CDK2JAK1 | |
| SCHEMBL4774057 | 0.84 | PRKCQ (0.56) | SYKAURKALRRK2PTK2KCNH2 | |
| SCHEMBL4774317 | 0.83 | AURKA (0.53) | SYKAURKAPTK2KCNH2PTK2B | |
| SCHEMBL4770588 | 0.82 | SYK (0.56) | SYKAURKALRRK2TBK1JAK2 | |
| SCHEMBL4766314 | 0.82 | SYK (0.71) | SYKCDK2JAK2JAK1 | |
| SCHEMBL4764141 | 0.81 | CDK2 (0.53) | SYKAURKALRRK2CDK2 | |
| SCHEMBL4772623 | 0.81 | SYK (0.54) | SYKAURKALRRK2JAK2JAK1 | |
| SCHEMBL4769132 | 0.81 | SYK (0.64) | SYKLRRK2CDK2JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1303496-B9 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-03-19 | — | — | EP | claimed |
| EP-1303496-B1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-09-12 | — | — | EP | claimed |
| US-6908920-B2 | Pyrimidine derivatives | ASTRAZENECA AB (SE) | 2005-06-21 | — | — | US | claimed |
| JP-2004502763-A | — | — | 2004-01-29 | — | — | JP | claimed |
| US-20030216406-A1 | Pyrimidine derivatives | ASTRAZENECA AB (SE) | 2003-11-20 | — | — | US | claimed |
| EP-1303496-A1 | PYRIMIDINE DERIVATIVES | AstraZeneca AB (SE) | 2003-04-23 | — | — | EP | claimed |
| WO-2002004429-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-01-17 | — | — | WO | claimed |
| EP-1303496-B9 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-03-19 | — | — | EP | disclosed |
| EP-1303496-B1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216406-A1 | Pyrimidine derivatives | TYMP, TYMS, CCNT1 | SYK 1334/4885AURKA 502/4885LRRK2 4334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.